Education

Optimizing the Management of Newly Diagnosed Ovarian Cancer Including Maintenance (Session 3 of 3)

Topics — Ovarian Cancer

Oct 9, 2023 | Education

Lung Cancer Screening and Identification of Lung Cancer Patients at All Stages (Session 2 of 3)

Topics — Lung Cancer

Jul 11, 2023 | Education

Personalizing Treatment in High Grade Glioma using 3D Ex Vivo Technology (Session 3 of 6)

Topics — high grade glioma

Jun 12, 2023 | Education

Expert Insights into Management of Advanced Triple Negative Breast Cancer (Session 1 of 3)

Topics — Breast Cancer

Jun 7, 2023 | Education

Using Live Patient-specific Tumor Tissue to Predict Therapeutic Response(s) in HGG Patients Before Treatment Initiation (Session 2 of 6)

Topics — high grade glioma

May 30, 2023 | Education

Functional Precision Oncology: Revolutionizing the Future of Cancer Care by Predicting Individual Patient Response(s) to Oncology Drugs (Session 1 of 6)

Topics — high grade glioma

Apr 25, 2023 | Education

Building and Engaging Affiliate Cancer Care Networks Webinar

Topics — cancer care affiliate networks

Mar 22, 2023 | Education

Quality Improvement Program Webinar—Breast and Ovarian Cancer Biomarker Testing

Topics — Breast Cancer, Ovarian Cancer

Mar 15, 2022 | Education

Quality Improvement Program Webinar—NSCLC Biomarker Testing

Topics — NSCLC

Mar 8, 2022 | Education

Lung Cancer Patient with 3 EGFR Mutations

Topics — EGFR, Lung Cancer

Apr 1, 2021 | Education

Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation

Topics — BRCA, Ovarian Cancer

Apr 1, 2021 | Education

Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations

Topics — BRCA, EGFR, Lung Cancer, Ovarian Cancer

Apr 1, 2021 | Education

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Topics — EGFR, Exon 19 Deletion, Lung Cancer, NSCLC

Mar 1, 2021 | Education

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

Topics — EGFR, Exon 19 Deletion, Lung Cancer

Mar 1, 2021 | Education

NSCLC Patient and Adjuvant Chemotherapy

Topics — EGFR, Lung Cancer, NSCLC

Mar 1, 2021 | Education

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Topics — Lung Cancer, NSCLC

Feb 1, 2021 | Education

Patient with NSCLC Who Recurred within a Year

Topics — EGFR, Lung Cancer, NSCLC

Feb 1, 2021 | Education

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Topics — EGFR, Exon 19 Deletion, Lung Cancer, NSCLC

Feb 1, 2021 | Education

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

Topics — EGFR, Exon 19 Deletion, Lung Cancer, NSCLC

Feb 1, 2021 | Education

MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations

Topics — ATM, Gastric Cancer, KIT Exon 11

Dec 1, 2020 | Education

Patient with Prostate Cancer and CDK12 and TP53 Mutations

Topics — CDK12, Prostate Cancer, TP53

Dec 1, 2020 | Education

UK Markey Learning Series

2,000,000+

143,000+

24,000+

Project ECHO® Learning Series

2,000,000+

118,000+

19,000+

Education

Optimizing the Management of Newly Diagnosed Ovarian Cancer Including Maintenance (Session 3 of 3)

Lung Cancer Screening and Identification of Lung Cancer Patients at All Stages (Session 2 of 3)

Personalizing Treatment in High Grade Glioma using 3D Ex Vivo Technology (Session 3 of 6)

Expert Insights into Management of Advanced Triple Negative Breast Cancer (Session 1 of 3)

Using Live Patient-specific Tumor Tissue to Predict Therapeutic Response(s) in HGG Patients Before Treatment Initiation (Session 2 of 6)

Functional Precision Oncology: Revolutionizing the Future of Cancer Care by Predicting Individual Patient Response(s) to Oncology Drugs (Session 1 of 6)

Building and Engaging Affiliate Cancer Care Networks Webinar

Quality Improvement Program Webinar—Breast and Ovarian Cancer Biomarker Testing

Quality Improvement Program Webinar—NSCLC Biomarker Testing

Lung Cancer Patient with 3 EGFR Mutations

Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation

Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations

NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients

Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result

NSCLC Patient and Adjuvant Chemotherapy

Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results

Patient with NSCLC Who Recurred within a Year

Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion

Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy

MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations

Patient with Prostate Cancer and CDK12 and TP53 Mutations